Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06972446 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis

StatusRecruiting
PhasePhase 2
SponsorAbbVie
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary endpoint removed 3 → 2 primary endpoints
Primary endpoint added 2 → 3 primary endpoints
See other at-risk trials from AbbVie

Record History

The 50 most recent of 84 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. Primary endpoint(s) modified Interventions modified · Trial arms changed: 12 → 6 · Eligibility criteria shortened, about 29 words · 2 more Show 5 more changesShow less
    • Interventions modified
    • Trial arms changed: 12 → 6
    • Eligibility criteria shortened, about 29 words
    • Secondary endpoints: 14 to 7
    • Study sites revised (96)
  2. Primary endpoint(s) modified Trial sites reduced: 104 → 96 locations · Interventions modified · Trial arms changed: 6 → 12 Show 3 more changesShow less
    • Trial sites reduced: 104 → 96 locations
    • Interventions modified
    • Trial arms changed: 6 → 12
  3. Trial sites expanded: 101 → 104 locationsv82
  4. Study sites: 100 to 101v81
  5. Study sites: 98 to 100v80
Show 7 earlier versionsHide 7 earlier versions
  1. Study sites: 97 to 98v79
  2. Study sites: 96 to 97v78
  3. Study sites: 94 to 96v77
  4. Study sites: 92 to 94v76
  5. Study sites: 91 to 92v75
  6. Study sites: 90 to 91v74
  7. Study sites: 89 to 90v73
  1. Trial sites reduced: 96 → 88 locationsv72
  2. Study sites: 96 to 88v71
  3. Trial sites expanded: 84 → 94 locationsv70
  4. Study sites: 94 to 95v69
  5. Study sites: 93 to 94v68
  6. Trial sites expanded: 71 → 83 locationsv67
  7. Study sites: 83 to 84v66
  8. Trial sites reduced: 79 → 71 locationsv65
  9. Trial sites expanded: 70 → 79 locationsv64
  10. Study sites: 70 to 79v63
  11. Study sites: 69 to 70v62
  12. 2 versions Re-verified since Mar 25, 2026, no change to tracked fieldsv60-v61
  13. Study sites: 68 to 69v59
  14. Study sites: 67 to 68v58
  15. Study sites: 66 to 67v57
  16. Re-verified, no change to tracked fieldsv56
  17. Study sites: 65 to 66v55
  18. Study sites: 63 to 65v54
  19. Study sites: 62 to 63v53
  20. Study sites: 61 to 62v52
  21. Study sites: 59 to 61v51
  22. Study sites: 58 to 59v50
  23. Re-verified, no change to tracked fieldsv49
  24. Study sites: 55 to 58v48
  25. Study sites: 54 to 55v47
  26. Study sites: 53 to 54v46
  27. Study sites: 52 to 53v45
  28. Study sites: 51 to 52v44
  29. Re-verified, no change to tracked fieldsv43
  30. Study sites: 50 to 51v42
  31. Study sites: 49 to 50v41
  32. 2 versions Re-verified since Jan 29, 2026, no change to tracked fieldsv39-v40
  33. Study sites: 47 to 49v38
  34. Re-verified, no change to tracked fieldsv37
  35. Study sites: 45 to 47v36
  36. Study sites: 44 to 45v35
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
AbbVie
345 trials monitored
See 27 trials at risk
Rheumatoid Arthritis
616 trials monitored
See 14 trials at risk
Rheumatoid Arthritis (RA) is a chronic inflammatory disease causing pain, stiffness, swelling and loss of joint function. This study will evaluate the efficacy and safety of targeted therapies through a series of substudies for the treatment of moderately to severely active Rheumatoid Arthritis (RA). This study currently includes 3 substudies evaluating different treatments in participants with RA. Substudy 1 will evaluate lutikizumab monotherapy (treatment given alone) compared to placebo (looks like the study treatment but contains no medicine). Substudy 2 will evaluate ravagalimab monotherapy compared to placebo and Substudy 3 will evaluate lutikizumab and ravagalimab combination therapy (treatments given together) compared to placebo. Approximately 180 participants who have failed 1 or 2 biologic/targeted synthetic disease-modifying antirheumatic drug (tsDMARD) therapies will be enrolled in the study at approximately 65 sites worldwide. There may be higher treatment burden for participants in this trial compared to their standard of care treatment without participating in this study. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Trial Details
NCT Number NCT06972446
Lead Sponsor AbbVie
Conditions Rheumatoid Arthritis
Enrollment 180 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov